Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Rhea-AI Summary

Citius Oncology (Nasdaq: CTOR) will present Phase 1 data on LYMPHIR (denileukin diftitox‑cxdl) plus pembrolizumab in relapsed/refractory gynecologic malignancies at the ASCO 2026 Annual Meeting in Chicago.

The investigator‑initiated trial reported a 24% objective response rate, average 21.1‑month duration of response in responders, and a favorable safety profile, which is described as signaling potential to augment immune checkpoint inhibitor efficacy and expand LYMPHIR’s role beyond CTCL.

The abstract (No. 2564) will be presented as a poster in the Developmental Therapeutics—Immunotherapy session on May 30, 2026, from 1:30 PM to 4:30 PM CDT.

News Market Reaction – CTOR

+2.39%

1 alert

+2.39% Session close to close

$75.53M Market Cap

0.4x Rel. Volume

In the May 26 session, CTOR gained 2.39%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights detailed Phase 1 combination data for LYMPHIR, including a 24% Objectiv...

Analysis

This announcement highlights detailed Phase 1 combination data for LYMPHIR, including a 24% Objective Response Rate and 21.1‑month average response duration, selected from over 8,500 ASCO abstracts. It reinforces prior investigator‑initiated results in gynecologic and other solid tumors. Investors may track how additional data readouts, commercialization progress, and capital needs disclosed in recent filings intersect with LYMPHIR’s emerging role in combination regimens.

Key Figures

Objective Response Rate: 24% Duration of Response: 21.1 months Abstract submissions: 8,500+ +5 more

8 metrics

Objective Response Rate 24% Phase 1 LYMPHIR plus pembrolizumab study responders

Duration of Response 21.1 months Average duration among responders in Phase 1 study

Abstract submissions 8,500+ Submissions reviewed for ASCO Scientific Program

ASCO meeting dates May 29–June 2, 2026 2026 American Society of Clinical Oncology Annual Meeting

Abstract number 2564 LYMPHIR Phase 1 combination study ASCO abstract ID

Poster board 354 Assigned poster board for ASCO presentation

Session time 1:30 PM–4:30 PM CDT Poster session on May 30, 2026

Attendees 35,000 Estimated oncology professionals at ASCO Annual Meeting

Previous Clinical trial Reports

4 past events · Latest: Mar 31 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 31	Clinical/commercial update	Positive	+25.7%	Early LYMPHIR launch metrics and expanding clinical development data.
Mar 10	Combo topline data	Positive	-0.5%	Positive topline Phase 1 LYMPHIR plus pembrolizumab data in gynecologic cancers.
Mar 04	CAR-T combo data	Positive	+2.8%	Preliminary Phase 1 LYMPHIR dosing before CD19 CAR‑T in high‑risk DLBCL.
Nov 11	Early combo results	Positive	+6.3%	Promising Phase I KEYTRUDA plus LYMPHIR data in recurrent solid tumors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial updates for LYMPHIR have generally led to positive price reactions, with three of four past events seeing gains and one small divergence.

Recent Company History

Over the past year, CTOR has repeatedly highlighted LYMPHIR’s expanding clinical profile. Updates included U.S. launch metrics and positive combination data with pembrolizumab and CAR‑T regimens, often presented at major meetings like ASTCT. These clinical‐trial announcements have usually been associated with gains, notably the Mar 31, 2026 update after which shares rose 25.74%. Today’s ASCO Phase 1 combination data builds directly on those prior investigator‑initiated results.

Key Terms

objective response rate, duration of response, immune checkpoint inhibitor, pembrolizumab, +4 more

8 terms

objective response rate medical

"24% Objective Response Rate, with an average of 21.1 month Duration of Response"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

duration of response medical

"24% Objective Response Rate, with an average of 21.1 month Duration of Response"

Duration of response is the length of time a patient’s condition stays improved after a treatment until it starts to worsen again; think of it as how long a freshly charged battery continues to power a device. For investors, longer duration of response implies a treatment provides sustained benefit, which can boost a drug’s commercial value, support stronger regulatory labeling and payer coverage, and reduce the need for additional therapies.

immune checkpoint inhibitor medical

"signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy"

An immune checkpoint inhibitor is a type of medicine that helps the body's immune system recognize and attack cancer cells more effectively. It works by blocking certain signals that cancer uses to hide from immune defenses, allowing the immune system to target tumors. This breakthrough has led to new cancer treatments, making immune checkpoint inhibitors an important area of growth and innovation in the healthcare industry.

pembrolizumab medical

"denileukin diftitox-cxdl in combination with the PD-1 immune checkpoint inhibitor pembrolizumab"

A cancer immunotherapy drug that helps the body’s immune system recognize and attack tumor cells by blocking a molecular “brake” that tumors use to hide. Investors watch it because regulatory approvals, clinical trial results, dosing rules, and competition directly affect potential sales, profit forecasts, and the valuation of companies that sell or license the drug—think of trial outcomes as checkpoint signs that can open or close a revenue road.

pd-1 medical

"in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA®)"

PD-1 is a protein found on certain immune cells that acts like a brake, signaling the immune system to slow down and avoid damaging healthy tissue. Drugs that block PD-1 release that brake so immune cells can better attack cancer cells; because such therapies can produce large clinical benefits, regulatory approvals, trial outcomes, pricing and market uptake for PD-1 drugs can materially affect a drugmaker’s prospects and investor returns.

t-regulatory cells medical

"Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination"

T-regulatory cells are a specialized type of immune cell that act like referees or brakes, calming or shutting down other immune responses to prevent excessive inflammation or attack on the body’s own tissues. They matter to investors because therapies that boost or block these cells can treat autoimmune diseases or cancer, affecting drug development prospects, regulatory risk, and market value for companies working on immune-based treatments.

relapsed/refractory medical

"pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results"

Relapsed/refractory describes a disease, usually cancer, that has returned after treatment (relapsed) or that did not respond to initial therapy (refractory). For investors this signals a high medical need and a defined patient group for new treatments — like a market of cars that won’t start with a standard key — which can affect drug development priorities, trial designs, potential pricing and commercial opportunity.

gynecologic malignancies medical

"pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results"

Cancers that originate in a woman’s reproductive organs—such as the uterus, ovaries, cervix, vulva and vagina—are grouped as gynecologic malignancies. They matter to investors because they define the size of potential patient markets, shape clinical trial and regulatory paths, and influence revenue from diagnostics, drugs and procedures; think of them as a neighborhood of related diseases that determine demand for specific medical products and services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

Investigator-initiated study of LYMPHIR in combination with pembrolizumab to be presented during immunotherapy session, highlighting potential role of LYMPHIR beyond CTCL

CRANFORD, N.J., May 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that University of Pittsburgh Medical Center's investigator-initiated trial evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA^®) has been selected for poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 29 – June 2, 2026, in Chicago, Illinois.

The abstract, submitted by investigators at the University of Pittsburgh Medical Center, was selected for presentation from more than 8,500 submissions reviewed by the ASCO Scientific Program Committee. The full abstract was made available on May 21, 2026, via the American Society of Clinical Oncology website.

"We are pleased to see this investigator-sponsored study selected for presentation at ASCO, reflecting continued clinical interest in denileukin diftitox-cxdl across multiple tumor types," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology. "We look forward to engaging with the clinical oncology community to discuss the encouraging topline Phase 1 data evaluating Treg cell suppression in combination with checkpoint inhibitors."

Abstract Details:

• Abstract Number: 2564
• Title: Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results
• Session Type: Poster Session – Developmental Therapeutics—Immunotherapy
• Poster Board: 354
• Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT   

The Phase 1 study evaluated the safety, tolerability, and preliminary activity of denileukin diftitox-cxdl in combination with pembrolizumab in patients with relapsed or refractory gynecologic malignancies.

The ASCO Annual Meeting is one of the world's largest and most influential oncology conferences, bringing together an estimated 35,000 oncology professionals from around the globe. The meeting serves as a premier forum for the presentation of cutting-edge cancer research, with abstracts selected through a highly competitive peer-review process.

About the Study

This open‑label, dose‑escalation, investigator‑initiated Phase 1 study (NCT05200559), led by Dr. Alexander B Olawaiye at UPMC Magee‑Women's Hospital, enrolled patients with recurrent or metastatic solid tumors who had received at least one prior line of therapy. LYMPHIR was administered intravenously on Days 1–3 of each 21‑day cycle at escalating doses (3, 6, 9, and 12 mcg/kg), along with pembrolizumab (200 mg IV) on Day 1. Patients who completed eight cycles of combination therapy were continued on pembrolizumab monotherapy until disease progression.

The use of LYMPHIR in this study was investigational and outside of its FDA-approved indication. The Phase 1 study was not designed or powered to evaluate clinical efficacy, and no conclusions can be drawn regarding comparative effectiveness or long-term outcomes.

About Gynecologic Cancers

Recurrent or metastatic ovarian and endometrial cancers are two of the most common gynecologic malignancies in the United States. Endometrial cancer is the most frequently diagnosed gynecologic cancer, with an estimated 70,000 new endometrial cancer cases expected in the United States in 2026¹, while ovarian cancer remains the deadliest with approximately 12,700 deaths per year (51.6%) and approximately 20,000 new diagnoses each year in the United States². These cancers are often detected at advanced stages, and although many patients initially respond to platinum‑based chemotherapy, most experience relapse and develop resistance. Survival rates in the recurrent setting remain poor, and responses to current immunotherapies such as PD‑1 inhibitors are limited, highlighting a significant unmet need for novel treatment approaches. LYMPHIR's transient depletion of regulatory T‑cells may enhance anti‑tumor immune responses and help overcome immunotherapy resistance in these difficult‑to‑treat tumors.

About LYMPHIR™ (denileukin diftitox‑cxdl)

LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.

In 2021, reformulated denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize reformulated denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025.

About Citius Oncology, Inc.

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with Nasdaq's continued listing standards; our ability to obtain, perform under and maintain third party agreements and relationships, including obtaining a new bulk drug substance supplier; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; early-stage clinical data may not be predictive of results from larger or later-stage studies; our ability to secure and maintain strategic partnerships and expand international access to LYMPHIR; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability to procure cGMP commercial-scale supply; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

REFERENCES:

1. American Cancer Society. Cancer Facts & Figures 2026 (projected). Atlanta: American Cancer Society; 2026. https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statistics.html
2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Uterine and Ovarian Cancer. https://seer.cancer.gov/statfacts/html/ovary.html

KEYTRUDA^® is a registered trademark of Merck & Co., Inc.

LYMPHIR™ (denileukin diftitox‑cxdl)

INDICATION

LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: CAPILLARY LEAK SYNDROME

Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.

WARNINGS AND PRECAUTIONS

Capillary Leak Syndrome

LYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <3 g/dL. These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome.

As defined, CLS occurred in 27% of patients in the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first 2 cycles of treatment. The median time to onset from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution. The most common symptoms included edema, hypoalbuminemia, and hypotension. Pleural effusion, pericardial effusion, and dehydration also occurred.

Regularly assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated.

Withhold, reduce dose, or permanently discontinue based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal to 3 g/dL.

Visual Impairment

LYMPHIR can cause serious visual impairment, including changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in 9%, with Grade 1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution of their visual impairment.

Perform baseline ophthalmic examination and monitor as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, or blurred vision, refer for ophthalmologic evaluation.

Withhold LYMPHIR until visual impairment resolves or permanently discontinue based on severity.

Infusion-Related Reactions

LYMPHIR can cause serious infusion-related reactions. Infusion-related reactions were reported in 69% of patients in the pooled population across 3 clinical trials of patients who received LYMPHIR, with Grade 3 infusion-related reactions in 3.4%. Eighty-three percent of infusion-related reactions occurred in Cycles 1 and 2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever, and arthralgia.

Premedicate patients for the first three cycles prior to starting a LYMPHIR infusion. Monitor patients frequently during infusion. For Grade 2 or higher infusion reactions, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles.

Interrupt or discontinue LYMPHIR based on severity. Institute appropriate medical management.

Hepatotoxicity

LYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was 8 days (range: 1 to 15 days); median time to resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved. Elevated total bilirubin occurred in 5% of patients, with Grade 3 occurring in 0.9%.

Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity.

Embryo-Fetal Toxicity

Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 days following the last dose of LYMPHIR.

ADVERSE REACTIONS

The most common adverse reactions (≥20%), including laboratory abnormalities, are increased transaminases, albumin decreased, nausea, edema, hemoglobin decreased, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome.

USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary
Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. There are no available data on the use of LYMPHIR in pregnant women to evaluate for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with denileukin diftitox.

Denileukin diftitox-cxdl causes depletion of regulatory T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy maintenance. Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.

Lactation

Risk Summary
No data are available regarding the presence of denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose.

Females and Males of Reproductive Potential

Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman.

Pregnancy Testing
Verify the pregnancy status of females of reproductive potential prior to initiating LYMPHIR.

Contraception

Females 
Advise females of reproductive potential to use effective contraception during treatment with LYMPHIR and for 7 days after the last dose.

Infertility

Males
Based on findings in rats, male fertility may be compromised by treatment with LYMPHIR. The reversibility of the effect on fertility is unknown.

Pediatric Use
Safety and effectiveness of LYMPHIR in pediatric patients have not been established.

Geriatric Use
Of the 69 patients with Stage I-III r/r CTCL who received LYMPHIR, 34 patients (49%) were 65 years of age and older and 10 patients (14%) were 75 years of age and older. Clinical studies of LYMPHIR did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. 

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Citius Oncology at 1-844-459-6744.

Please read Important Safety Information and full Prescribing Information, including Boxed WARNING, for LYMPHIR.

Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-announces-presentation-of-lymphir-phase-1-combination-study-data-at-the-2026-american-society-of-clinical-oncology-annual-meeting-302781496.html

SOURCE Citius Oncology, Inc.

FAQ

What ASCO 2026 data is Citius Oncology (NASDAQ:CTOR) presenting on LYMPHIR?

Citius Oncology will present Phase 1 data on LYMPHIR plus pembrolizumab in relapsed/refractory gynecologic cancers. According to Citius Oncology, the study assessed safety, tolerability, and preliminary activity, including objective response rate, duration of response, and T‑regulatory cell depletion with checkpoint inhibitor therapy.

What are the key Phase 1 results for LYMPHIR in combination with pembrolizumab reported by CTOR?

According to Citius Oncology, the Phase 1 study showed a 24% objective response rate and an average 21.1‑month duration of response among responders. The company also reports a favorable safety profile, suggesting potential for LYMPHIR to enhance immune checkpoint inhibitor efficacy in gynecologic malignancies.

When and where will Citius Oncology (CTOR) present its LYMPHIR ASCO 2026 poster?

The LYMPHIR Phase 1 combination data will be presented at ASCO 2026 in Chicago on May 30, 2026, from 1:30 PM to 4:30 PM CDT. According to Citius Oncology, the poster appears in the Developmental Therapeutics—Immunotherapy session, abstract number 2564.

What is the focus of the LYMPHIR plus pembrolizumab Phase 1 study highlighted by Citius Oncology?

The Phase 1 study focuses on safety, tolerability, and preliminary activity of LYMPHIR with pembrolizumab in relapsed/refractory gynecologic cancers. According to Citius Oncology, investigators are evaluating T‑regulatory cell depletion and how this combination may improve immune checkpoint inhibitor treatment outcomes.

Why is the LYMPHIR ASCO 2026 presentation important for Citius Oncology (CTOR) investors?

The ASCO 2026 presentation showcases early combination data that may broaden LYMPHIR’s use beyond CTCL. According to Citius Oncology, the 24% response rate, long response duration, and safety profile support further exploration of LYMPHIR with checkpoint inhibitors in gynecologic malignancies.